Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Sun PC, Uppaluri R, Schmidt AP, et al. Transcript map of the 8p23 putative tumor suppressor region. Genomics. 2001;75(1–3):17–25. doi:10.1006/geno.2001.6587
   PubMed Web of Science ®Google Scholar
• Lau WL, Scholnick SB. Identification of two new members of the CSMD gene family. Genomics. 2003;82(3):412–415. doi:10.1016/S0888-7543(03)00149-6
   PubMed Web of Science ®Google Scholar
• Shimizu A, Asakawa S, Sasaki T, et al. A novel giant gene CSMD3 encoding a protein with CUB and sushi multiple domains: a candidate gene for benign adult familial myoclonic epilepsy on human chromosome 8q23.3-q24.1. Biochem Biophys Res Commun. 2003;309(1):143–154. doi:10.1016/S0006-291X(03)01555-9
   PubMed Web of Science ®Google Scholar
• Kraus DM, Elliott GS, Chute H, et al. CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol. 2006;176(7):4419–4430. doi:10.4049/jimmunol.176.7.4419
   PubMed Web of Science ®Google Scholar
• Escudero-esparza A, Kalchishkova N, Kurbasic E, Jiang WG, Blom AM. The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly. FASEB j. 2013;27(12):5083–5093. doi:10.1096/fj.13-230706
   PubMed Web of Science ®Google Scholar
• Athanasiu L, Giddaluru S, Fernandes C, et al. A genetic association study of CSMD1 and CSMD2 with cognitive function. Brain Behav Immun. 2017;61:209–216. doi:10.1016/j.bbi.2016.11.026
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng Z, Wang J, et al. No association between the rs10503253 polymorphism in the CSMD1 gene and schizophrenia in a Han Chinese population. BMC Psychiatry. 2016;16:206. doi:10.1186/s12888-016-0923-5
   PubMed Web of Science ®Google Scholar
• Liu W, Liu F, Xu X, Bai Y. Replicated association between the European GWAS locus rs10503253 at CSMD1 and schizophrenia in Asian population. Neurosci Lett. 2017;647:122–128. doi:10.1016/j.neulet.2017.03.039
   PubMed Web of Science ®Google Scholar
• Shahmohammadibeni N, Rahimi-aliabadi S, Jamshidi J, et al. The analysis of association between SNCA, HUSEYO and CSMD1 gene variants and Parkinson’s disease in Iranian population. Neurol Sci. 2016;37(5):731–736. doi:10.1007/s10072-015-2420-x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang S, Kang W, et al. CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation. Oncogene. 2018;37(26):3485–3500. doi:10.1038/s41388-018-0161-z
   PubMed Web of Science ®Google Scholar
• Zhang R, Song C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumour Biol. 2014;35(5):4419–4423. doi:10.1007/s13277-013-1581-6
   PubMedGoogle Scholar
• Shull AY, Clendenning ML, Ghoshal-gupta S, et al. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PLoS One. 2013;8(3):e58731. doi:10.1371/journal.pone.0058731
   PubMed Web of Science ®Google Scholar
• Ma C, Quesnelle KM, Sparano A, et al. CharacterizationCSMD1in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther. 2014;8(10):907–916. doi:10.4161/cbt.8.10.8132
   Web of Science ®Google Scholar
• Tang MR, Wang YX, Guo S, Han SY, Wang D. CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis. 2012;17(9):927–937. doi:10.1007/s10495-012-0727-0
   PubMed Web of Science ®Google Scholar
• Skidmore ZL, Wagner AH, Lesurf R, et al. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32(19):3012–3014. doi:10.1093/bioinformatics/btw325
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275. doi:10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• Wang VE, Urisman A, Albacker L, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017;5(1):75. doi:10.1186/s40425-017-0281-y
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Buder-bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474. doi:10.3389/fimmu.2018.01474
   PubMed Web of Science ®Google Scholar
• Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol. 2016;11(7):976–988. doi:10.1016/j.jtho.2016.02.015
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith K, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Lee V, Murphy A, Le DT, Diaz LA JR. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21(10):1200–1211.
   PubMed Web of Science ®Google Scholar
• Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29(3):285–296. doi:10.1016/j.ccell.2016.02.004
   PubMed Web of Science ®Google Scholar